Navigation Links
New findings could influence the development of therapies to treat dengue disease
Date:8/2/2013

New research into the fight against Dengue, an insect-borne tropical disease that infects up to 390 million people worldwide annually, may influence the development of anti-viral therapies that are effective against all four types of the virus.

The findings, led by researchers at the University of Bristol and published in the Journal of Biological Chemistry today [2 August], show for the first time that there may be significant differences in specific properties of the viral proteins for the four dengue virus types.

Due to the effects of globalisation, including increased travel and urbanisation of human populations and the expanded geographical distribution of the mosquito vector that is responsible for the transmission of viral infections to millions of people, the number of individuals afflicted with dengue is rising.

Infection with any one of the four types of dengue virus (DENV types 1 - 4) may result in a spectrum of illnesses ranging from dengue fever, a mild flu like illness which causes high fever and joint pains, to the potentially fatal dengue haemorrhagic fever. Despite intensive research, dengue disease is not wholly understood, and there are no vaccines or anti-viral treatments available that can safely or effectively control the disease.

Dr Andrew Davidson, Senior Virologist and lead researcher from the University of Bristol, and colleagues examined the nuclear localisation properties of the NS5 protein of all four DENV types and found that there are major differences in the cellular localisation of the viral NS5 protein for the four DENV types.

The four types of DENV are genetically distinct. Although they can all cause dengue disease, little is known about how the genetic differences between them may translate into differences in virus replication and pathogenesis.

Previous studies by the team focusing on DENV-2, have shown that the viral NS5 protein is essential for DENV genome replication and is able to modulate the host immune response. As such, the NS5 protein is a key target for the development of anti-viral agents. Importantly, the team also showed that the DENV-2 NS5 protein accumulates in the nucleus during infection which is believed to effect host cell function.

Dr Davidson, Senior Lecturer in Virology, School of Cellular and Molecular Medicine at the University of Bristol, said: "The study shows for the first time that there may be significant differences in specific properties of the viral proteins for the four DENV types. This is important as it impacts on our understanding of viral replication and pathogenesis and the design of anti-viral therapies that are effective against all DENV types."

Present studies in the laboratory are focused on comprehensively comparing the effects of different DENV types on the host cell, using the state-of-the-art proteomics facilities at the University of Bristol.


'/>"/>

Contact: Philippa Walker
philippa.walker@bristol.ac.uk
44-117-928-7777
University of Bristol
Source:Eurekalert

Related medicine news :

1. New findings in breast cancer
2. Kessler Foundation scientists present cognitive research findings at MS dual symposium
3. Researchers present new findings for novel pancreatic cancer vaccine
4. Mayo Clinic urologists present findings at American Urological Association Annual Meeting
5. Once-Banned Bird Flu Study Yields Sobering Findings
6. Columbus Allergist Dr. Summit Shah Discusses Recent Findings on Food Allergies and Exercise-Induced Anaphylaxis
7. Relief for Migraine Sufferers as The Life House Offers New Findings, Free Consults
8. New findings by GW researcher break tanning misconceptions: There is no such thing as a safe tan
9. MRI findings shed light on multiple sclerosis
10. Unexpected findings at multi-detector CT scans: Less reason to worry
11. New findings on mens genes could alter interpretation of PSA test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... From June 20-22, EarQ and ... in Syracuse, New York, where EarQ is headquartered. , Together, the organizations educate ... with today’s savvy consumer, and the latest in hearing technology. At the event, ...
(Date:6/27/2017)... ... June 27, 2017 , ... Atmosera , ... Atmosera Managed Azure Services . The trusted, transparent, and secure solution for the ... growing customer base. Atmosera’s next generation services include integrated capabilities for public, private, ...
(Date:6/27/2017)... ... June 27, 2017 , ... A+ Orthodontics is ... specialty that focuses on treating alignment and occlusion irregularities. Treatment often includes the ... , North Hollywood dentist , Dr. Garemani, along with Dr. Reza and ...
(Date:6/26/2017)... ... June 26, 2017 , ... Dr. Martin Bastuba, MD, FACS, ... with the Fertility Center of California, is pleased to announce the addition of ... and TESA (percutaneous testicular sperm extraction). These minimally invasive treatments are primarily used ...
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... ... coding staff, and consumers are seeing lots of red these days. According to ... inaccurate charges that result from medical coding errors(1). Some studies point to Electronic ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... GAITHERSBURG, Md. , June 7, 2017  Novavax, Inc., ... the second of two Phase 2 trials of its RSV ... women of child bearing age have been published in the ... this publication have been shared in prior scientific conferences). The ... trial in April 2014. Novavax is developing the RSV F ...
(Date:6/2/2017)... 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical ... new findings demonstrating positive biochemical outcomes related to more ... The data will be presented at the ERA-EDTA Congress ... Spain . The research was ... Network in Europe (KIHDNEy) ...
(Date:5/29/2017)... AVIV, Israel, May 29, 2017  Cellect Biotechnology Ltd. ... innovative technology which enables the functional selection of stem ... results for the first quarter ended March 31 st ... with our accomplishments in the first quarter of 2017," ... first quarter, we announced the treatment of the first ...
Breaking Medicine Technology: